NCT05069818

Variance of HRD From Paired Ovarian Cancer

Variance of HRD From Primary to Recurrent in High-grade Serous Ovarian Cancer

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 50 (estimated)
• Sponsor: Xiaoxiang Chen · Academic / Other
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Homologous recombination deficiency (HRD) is an important biomarker of poly (ADP-ribose) polymerase inhibitor (PARPi) in patients with high-grade serous ovarian cancer (HGSOC). The stability of HRD in the recurrent HGSOC and its primary pair remains unknown.

Detailed description

This study intends to perform HRD testing of ovarian cancer in the recurrent HGSOC and its primary pair, furtherly correlate HRD status and clinical characteristics in the recurited population.

Conditions

• Ovarian Cancer
• HRD
• Platinum-sensitive Ovarian Cancer

Timeline

• Start date: 2021-10-01
• Primary completion: 2022-10-01
• Completion: 2022-12-01
• First posted: 2021-10-06
• Last updated: 2021-10-06

Locations

1 site across 1 country: China